No profile data available.
NKGen Biotech, Inc. (NKGN) is a healthcare company in the brain and nerve treatment drugs industry, based in Santa Ana, United States, with about 26 full-time employees.
In Q1 2025 (the quarter ended March 31, 2025) revenue was $0. Its market capitalization was $7.84 million as of February 5, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of February 5, 2026.
, a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States.
$7.84 million as of February 5, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Brainstorm Cell Therapeutics Inc. (BCLI), Vistagen Therapeutics, Inc. (VTGN), Aeon Biopharma, Inc. (AEON), NeuroSense Therapeutics Ltd. (NRSN).